High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) – Pipeline Review, H2 2017’, provides in depth analysis on High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Oncology, Immunology, Dermatology, Metabolic Disorders and Ophthalmology under development targeting High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)

The report reviews High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Array BioPharma Inc

Astellas Pharma Inc

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Dompe Farmaceutici SpA

Genzyme Corp

Handok Inc

Ignyta Inc

Loxo Oncology Inc

Merck & Co Inc

Nerviano Medical Sciences Srl

Plexxikon Inc

Proximagen Ltd

Rottapharm Biotech Srl

Sienna Biopharmaceuticals Inc

Tiziana Life Sciences Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC

2.7.10.1) - Overview 9

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC

2.7.10.1) - Therapeutics Development 10

Products under Development by Stage of Development 10

Products under Development by Therapy Area 11

Products under Development by Indication 12

Products under Development by Companies 16

Products under Development by Universities/Institutes 22

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC

2.7.10.1) - Therapeutics Assessment 24

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC

2.7.10.1) - Companies Involved in Therapeutics Development 30

Array BioPharma Inc 30

Astellas Pharma Inc 30

AstraZeneca Plc 31

Daiichi Sankyo Co Ltd 31

Dompe Farmaceutici SpA 32

Genzyme Corp 32

Handok Inc 33

Ignyta Inc 33

Loxo Oncology Inc 34

Merck & Co Inc 35

Nerviano Medical Sciences Srl 36

Plexxikon Inc 36

Proximagen Ltd 37

Rottapharm Biotech Srl 37

Sienna Biopharmaceuticals Inc 38

Tiziana Life Sciences Plc 38

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC

2.7.10.1) - Drug Profiles 40

ACD-855 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

AR-523 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ARRY-954 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ASP-7962 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

AZD-7451 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

BNN-27 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

cenegermin - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

CRB-0089 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

DS-6051 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

entrectinib - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

GZ-389988 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

larotrectinib - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

milciclib - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Monoclonal Antibody to Inhibit TrkA for Central Nervous System Disorders and Peripheral Nervous System Disorders - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

NMSP-626 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

NOV-1601 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

PLX-7486 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecule to Inhibit TrkA for Inflammatory Pain - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecules to Agonize TrkA and TrkB for Alzheimer’s Disease - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Small Molecules to Inhibit TRK1 for Pain - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

SNA-120 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

SNA-125 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC

2.7.10.1) - Dormant Products 86

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC

2.7.10.1) - Discontinued Products 89

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC

2.7.10.1) - Product Development Milestones 91

Featured News & Press Releases 91

Oct 24, 2017: Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120 91

Oct 19, 2017: AlzeCure to Present Data on NeuroRestore Project at 10th annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD) 92

Oct 18, 2017: Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset 92

Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors 93

Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer 93

Oct 17, 2017: Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer 94

Sep 27, 2017: Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer 95

Sep 11, 2017: Ignyta to Provide Update on Entrectinib at ESMO 2017 Congress 96

Sep 07, 2017: Ignyta To Host Conference Call And Live Webcast On September 11 To Provide Pipeline Review, Including Lead Candidate Entrectinib 96

Sep 06, 2017: Ignyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program 96

Aug 31, 2017: Daiichi Sankyo to Present Data on Tumor Drug Candidate DS-6051 at the European Society for Medical Oncology 2017 Congress 97

Aug 30, 2017: Ignyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017 98

Jul 20, 2017: Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompe Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy 98

Jul 19, 2017: Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma 99

Jul 10, 2017: Dompe Farmaceutici Receives EU marketing authorisation For OXERVATE 100

Appendix 101

Methodology 101

Coverage 101

Secondary Research 101

Primary Research 101

Expert Panel Validation 101

Contact Us 101

Disclaimer 102

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Indications, H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15

Number of Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 21

Number of Products under Investigation by Universities/Institutes, H2 2017 22

Products under Investigation by Universities/Institutes, H2 2017 23

Number of Products by Stage and Mechanism of Actions, H2 2017 25

Number of Products by Stage and Route of Administration, H2 2017 27

Number of Products by Stage and Molecule Type, H2 2017 29

Pipeline by Array BioPharma Inc, H2 2017 30

Pipeline by Astellas Pharma Inc, H2 2017 31

Pipeline by AstraZeneca Plc, H2 2017 31

Pipeline by Daiichi Sankyo Co Ltd, H2 2017 32

Pipeline by Dompe Farmaceutici SpA, H2 2017 32

Pipeline by Genzyme Corp, H2 2017 33

Pipeline by Handok Inc, H2 2017 33

Pipeline by Ignyta Inc, H2 2017 34

Pipeline by Loxo Oncology Inc, H2 2017 35

Pipeline by Merck & Co Inc, H2 2017 36

Pipeline by Nerviano Medical Sciences Srl, H2 2017 36

Pipeline by Plexxikon Inc, H2 2017 37

Pipeline by Proximagen Ltd, H2 2017 37

Pipeline by Rottapharm Biotech Srl, H2 2017 38

Pipeline by Sienna Biopharmaceuticals Inc, H2 2017 38

Pipeline by Tiziana Life Sciences Plc, H2 2017 39

Dormant Products, H2 2017 86

Dormant Products, H2 2017 (Contd..1), H2 2017 87

Dormant Products, H2 2017 (Contd..2), H2 2017 88

Discontinued Products, H2 2017 89

Discontinued Products, H2 2017 (Contd..1), H2 2017 90

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Top 10 Indications, H2 2017 12

Number of Products by Mechanism of Actions, H2 2017 24

Number of Products by Stage and Mechanism of Actions, H2 2017 24

Number of Products by Routes of Administration, H2 2017 26

Number of Products by Stage and Routes of Administration, H2 2017 26

Number of Products by Molecule Types, H2 2017 28

Number of Products by Stage and Molecule Types, H2 2017 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports